Details of the Drug

General Information of Drug (ID: DMO3WV0)

Drug Name

ITIL-168

Indication

Disease Entry	ICD 11	Status	REF
Melanoma	2C30	Phase 2	[1]
------------------------------------------------------------------------------------

Drug Type

Cell therapy

Cross-matching ID

References

1	ClinicalTrials.gov (NCT05050006) A Phase 2, Open-label, Multicenter Study Evaluating the Safety and Efficacy of Autologous Tumor-infiltrating Lymphocytes (TILs) in Subjects With Advanced Melanoma (DELTA-1). U.S.National Institutes of Health.